Stocks · News reference
Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-02 AccNo: 0001193125-26-379423 Size: 131 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
AstraZeneca announced that its phase III SERENA-4 study evaluating Etcamah combined with Pfizer's Ibrance failed to meet its primary endpoint of progression-free survival as first-line treatment for ER-positive, HER2-negative advanced breast cancer, though numerical improvement was observed. The failure does not affect Etcamah's recent FDA approval for a switch strategy in patients with ESR1 resistance mutations.
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.